Atlas Trials

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Clinical trial NCT03528642 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03528642
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Astrocytoma, IDH-Mutant, Grade 2Astrocytoma, IDH-Mutant, Grade 3
Start date
2019-05-01
Primary completion
2026-09-11
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.